ESSAG试验协议:一项随机对照试验,评估一般医生提供自取样套件的有效性,以达到在常规宫癌查计划中被强调的妇女
Eva Gezels1, Kaatje Van Roy1, Marc Arbyn2
1Department of Public Health and Primary Care, Ghent University, C Heymanslaan 10, 9000 Ghent, Belgium.
Contemporary clinical trials
|July 8, 2024
概括
提供自取样套件 (SSK) 的全科医生可能会增加那些通常不定期参加查的女性的宫癌 (CC) 查参与率. 这一战略旨在提高CC查覆盖率的低于最佳水平.
科学领域:
- 在瘤学瘤学.
- 公共卫生 公共卫生
- 预防医学 预防医学
背景情况:
- 在比利时弗兰德斯的宫癌 (CC) 查覆盖率低于最佳,为63%.
- 目前的查依赖于来自癌症检测中心 (CCD) 的邀请,但参与率仍然很低.
- 提供自取样套件 (SSKs) 的全科医生可以提高未经查的人群的查率.
研究的目的:
- 评估基于GP的干预措施的有效性,使用SSK来增加CC查参与率.
- 评估在例行商期间提供的SSK与邮寄邀请的影响.
- 确定接触难以接触的人群进行CC查的策略.
主要方法:
- 一个集群随机对照试验 (ESSAG-试验) 涉及3360名年龄在31-64岁的女性,在过去6年中未进行CC查.
- 三个手臂:A臂 (GP在咨询期间提供SSK),B臂 (GP签名的邀请与SSK邮寄回家),控制 (标准CCD信).
- 主要结局:3个月后的响应率. 二次结果:积极性,后续合规性,成本和社会人口结构差异.
主要成果:
- 该ESSAG试验正在进行中,结果正在等待.
- 研究设计允许直接比较不同的干预策略.
- 分析将包括响应率,查阳性,后续合规性和成本效益.
结论:
- 使用SSK的基于GP的干预措施显示出增加CC查参与的希望.
- 调查结果将指导政策制定者实施有效的战略,以提高整个地区的查率.
- 该研究旨在改善CC查覆盖率,特别是在对当前计划的遵守程度较低的人群中.
相关概念视频
Randomized Experiments
The randomization process involves assigning study participants randomly to experimental or control groups based on their probability of being equally assigned. Randomization is meant to eliminate selection bias and balance known and unknown confounding factors so that the control group is similar to the treatment group as much as possible. A computer program and a random number generator can be used to assign participants to groups in a way that minimizes bias.
Simple randomization
Simple...
Simple randomization
Simple...
Comparing the Survival Analysis of Two or More Groups
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...
Hazard Ratio
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
For example, in a clinical trial evaluating a...


